Sugi Predict

Sugi Predict / Targets / ROS1

ROS1

Proto-oncogene tyrosine-protein kinase ROS · P08922 · ROS1 on Sugi Atlas →

83,193 patent compounds predicted against ROS1, 63,352 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL282757 SCHEMBL282757 1.00 18/20
SCHEMBL282319 SCHEMBL282319 1.00 14/20
SCHEMBL282586 SCHEMBL282586 1.00 14/20
SCHEMBL282587 SCHEMBL282587 1.00 14/20
SCHEMBL282668 SCHEMBL282668 1.00 14/20
SCHEMBL282669 SCHEMBL282669 1.00 14/20
SCHEMBL282224 SCHEMBL282224 0.87 14/20
SCHEMBL282408 SCHEMBL282408 1.00 13/20
SCHEMBL282409 SCHEMBL282409 1.00 13/20
SCHEMBL282415 SCHEMBL282415 1.00 13/20
SCHEMBL282486 SCHEMBL282486 1.00 13/20
SCHEMBL282487 SCHEMBL282487 1.00 13/20
Gilteritinib Gilteritinib (SCHEMBL282229) 1.00 12/20
SCHEMBL282332 SCHEMBL282332 0.87 12/20
SCHEMBL282569 SCHEMBL282569 0.87 12/20
SCHEMBL282410 SCHEMBL282410 0.80 12/20
SCHEMBL282411 SCHEMBL282411 0.80 12/20
SCHEMBL282396 SCHEMBL282396 0.78 12/20
SCHEMBL282103 SCHEMBL282103 0.77 12/20
SCHEMBL282104 SCHEMBL282104 0.77 12/20

Clinical trials — most relevant to ROS1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer PHASE2/PHASE3RECRUITING
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers. PHASE2/PHASE3RECRUITING
Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC PHASE1/PHASE2RECRUITING
A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors PHASE1/PHASE2COMPLETED
Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer. PHASE2NOT_YET_RECRUITING
A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer PHASE2WITHDRAWN
Sintilimab After Stereotactic Ablation Brachytherapy for Refractory Oligometastatic Non-Small Cell Lung Cancer PHASE2UNKNOWN
Natural Killer(NK) Cell Combined With Programmed Death-1(PD-1) Antibody as Second Line Therapy for Advanced Driver Mutation Negative Non-small Cell Lung Cancer PHASE2COMPLETED
Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLC PHASE2NOT_YET_RECRUITING
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) PHASE1/PHASE2RECRUITING
Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial) PHASE2ACTIVE_NOT_RECRUITING
A Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement PHASE2UNKNOWN
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors PHASE1/PHASE2RECRUITING
Evaluation of GLR2007 for Advanced Solid Tumors PHASE1/PHASE2COMPLETED
A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer PHASE2COMPLETED
Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS) PHASE2UNKNOWN
A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer PHASE1RECRUITING
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b PHASE1COMPLETED
A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer PHASE1RECRUITING
Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases PHASE1RECRUITING
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion EARLY_PHASE1RECRUITING
Circulating Tumor DNA Guided Treatment Monitoring in Advanced Lung Cancer nanRECRUITING
Local Therapy in Advanced NSCLC With Non-progressive Disease (PD) After First Line Therapy nanRECRUITING
Clinical and Molecular Study With Digital Support of Patients With Inoperable Lung Cancer nanCOMPLETED
Achieving Value in Cancer Diagnostics: Blood Versus Tissue Molecular Profiling - a Prospective Canadian Study nanCOMPLETED
Prospective Observation of Failure Patterns in NSCLC Treated With ICIs nanUNKNOWN
Epidemiologic Multicenter Prospective Study in Advanced NSCLC (Non Small Cell Lung Cancer) Patients With PDL1 (Protein Death Ligand 1) Expression. nanCOMPLETED
Validation of Molecular Diagnostic Thecnologies for Lung Cancer Patients. nanCOMPLETED
Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLC nanNOT_YET_RECRUITING
Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a ROS1 binder may also engage these)

ProteinNameSimilarity
Q78DX7 — 1.000 Q78DX7 →
Q63132 — 0.999 Q63132 →
Q00495 — 0.995 Q00495 →
O18016 — 0.994 O18016 →
Q75ZY9 — 0.993 Q75ZY9 →
Q07DZ1 — 0.993 Q07DZ1 →
Q2QLA9 — 0.993 Q2QLA9 →
Q09YK0 — 0.993 Q09YK0 →
Q8AXC7 — 0.992 Q8AXC7 →
Q108U6 — 0.992 Q108U6 →
Q28889 — 0.992 Q28889 →
P08941 — 0.991 P08941 →
Q2HWD6 — 0.991 Q2HWD6 →
Q28317 — 0.991 Q28317 →
Q7RTY8 — 0.990 Q7RTY8 →
A0M8R7 — 0.990 A0M8R7 →
P97523 — 0.990 P97523 →
P16056 — 0.990 P16056 →
Q76II0 — 0.990 Q76II0 →
Q09YH7 — 0.990 Q09YH7 →
KDR Vascular endothelial growth factor receptor 2 0.990 landscape →
MET Hepatocyte growth factor receptor 0.990 landscape →
Q91909 — 0.990 Q91909 →
Q2QLH6 — 0.989 Q2QLH6 →
E9Q7R9 — 0.989 E9Q7R9 →
CSF1R Macrophage colony-stimulating factor 1 receptor 0.989 landscape →
E2RK30 — 0.989 E2RK30 →
O88307 — 0.989 O88307 →
Q9DE49 — 0.989 Q9DE49 →
P79750 — 0.989 P79750 →